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Summary
Background Tuberculosis in children is increasingly recognised as an important component of the global tuberculosis 
burden, with an estimated 1 million cases in 2015. Although younger children are vulnerable to severe forms of 
tuberculosis disease, no age-disaggregated estimates of paediatric tuberculosis mortality exist, and tuberculosis has 
never been included in official estimates of under-5 child mortality. We aimed to produce a global mortality burden 
estimate in children using a complementary approach not dependent on vital registration data.
Methods In this mathematical modelling study, we estimated deaths in children younger than 5 years and those aged 
5–14 years for 217 countries and territories using a case-fatality-based approach. We used paediatric tuberculosis 
notification data and HIV and antiretroviral treatment estimates to disaggregate the WHO paediatric tuberculosis 
incidence estimates by age, HIV, and treatment status. We then applied systematic review evidence on corresponding 
case-fatality ratios.
Findings We estimated that 239 000 (95% uncertainty interval [UI] 194 000–298 000) children younger than 15 years 
died from tuberculosis worldwide in 2015; 80% (191 000, 95% UI 132 000–257 000) of these deaths were in children 
younger than 5 years. More than 70% (182 000, 140 000–239 000) of deaths occurred in the WHO southeast Asia and 
Africa regions. We estimated that 39 000 (17%, 23 000–73 000) paediatric tuberculosis deaths worldwide were in 
children with HIV infections, with 31 000 (36%, 19 000–59 000) in the WHO Africa region. More than 96% (230 000, 
185 000–289 000) of all tuberculosis deaths occurred in children not receiving tuberculosis treatment.
Interpretation Tuberculosis is a top ten cause of death in children worldwide and a key omission from previous 
analyses of under-5 mortality. Almost all these deaths occur in children not on tuberculosis treatment, implying 
substantial scope to reduce this burden.
Funding UNITAID, National Institutes of Health, and National Institute for Health Research.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
In 2015, under-5 mortality—deaths in children younger 
than 5 years—was estimated to be 5·9 million.1 This 
health statistic was a key indicator in the Millennium 
Development Goals2 and the subsequent Sustainable 
Development Goals.3 The UN Inter-agency Group on 
Child Mortality Estimation (IGME) tracks overall under-5 
mortality, and breakdowns by cause of death have been 
estimated by the study group formerly known as the 
Child Health Epidemiology Reference Group (CHERG), 
most recently in 2016.1 These estimates have been 
important in assessing progress towards targets, 
directing public health funding and spending, and for 
advocacy. However, tuberculosis has never been explicitly 
mentioned in these reports.
Tuberculosis, an infectious disease caused by bacteria 
and spread through the air, is the leading infectious cause 
of death worldwide. Although tuberculosis is curable, 
diagnostic methods for tuberculosis are imperfect and 
perform poorly in children because of difficulties 
obtaining samples and low bacillary loads. WHO first 
estimated total, both HIV-negative and HIV-positive, 
childhood tuberculosis mortality in 2015 and estimated 
that 136 000 children died from tubercu losis in 2014.4 This 
estimate increased substantially to 210 000 deaths for 
2015, because of data updates in countries informing the 
imputation model used to disaggregate mortality by age 
and the overall increase of the envelope of total mortality 
for all ages.5 This mortality estimate is based on vital 
registration data when available, and regression models 
incorporating national indicators when vital registration 
data are unavailable. IGME and CHERG methods are 
also based on civil and vital registration data, but also use 
survey data (including verbal autopsy for cause of death) 
when these are not available.
Direct approaches for estimating tuberculosis 
mortality use either vital registration data, adjusting for 
ill-defined causes of death, or verbal autopsy data; both 
are problematic for children. Recent estimates of 
childhood tuberculosis incidence suggest a substantially 
larger incidence of tuberculosis in children than 
previously appreciated or directly reflected in 
notification data, with more than 60% of cases 
unreported or undiagnosed—almost twice the 
corresponding proportion in adults.4,6–8 Large numbers 
of undiagnosed tuberculosis cases in children present 
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difficulties for vital-registration-based estimates of 
mortality since the cause of death in children who die 
from undiagnosed tuberculosis is likely to be recorded 
as something else, usually another common disease 
with which the signs and symptoms of tuberculosis 
overlap. For example, many deaths attributed to 
pneumonia in places with high tuberculosis burdens 
might actually be due to tuberculosis.9,10 Furthermore, 
even if a child is known to have died from tuberculosis, 
this might not be correctly recorded by weak or absent 
vital registration systems, common in many countries 
with high tuberculosis burdens.11,12 Even with good vital 
registration systems, the rules of the International 
Statistical Classification of Diseases and Related Health 
Problems-10 (ICD-10) coding system state that 
tuberculosis should not be registered as the primary 
cause of death when another comorbidity such as HIV 
is present; moreover, recorded secondary causes of 
death are often not relayed to supranational bodies.13 
Finally, verbal autopsy has limited sensitivity for 
tuberculosis deaths,14,15 especially in children because of 
diverse and non-specific signs and symptoms.16 Thus, 
both the current magnitude of underdiagnosis in 
children and restrictions in the availability and quality 
of direct population-level data lead to substantial 
uncertainty that is difficult to quantify in estimates 
based on these data sources.
An orthogonal and complementary method to 
estimate childhood tuberculosis mortality is based on 
multiplying incidence estimates by case-fatality ratios. 
This approach requires a good understanding of case-
fatality ratios for tuberculosis in children, by age, 
tuberculosis-treatment status and HIV status (both on 
and off antiretroviral therapy [ART]), and credible 
estimates of incidence. An understanding of the effects 
of HIV and ART status on tuberculosis risk in children 
is also needed to disaggregate incidence by these 
factors. Although such an approach makes general-
isations about the application of standard case-fatality 
ratios to different settings, it is robust in its relative 
independence from data sources of inconsistent 
availability and quality.
In this analysis, we reassess mortality due to 
tuberculosis in children younger than 5 years and those 
aged 5–14 years using a case-fatality approach, taking 
advantage of recent tuberculosis incidence estimates, 
systematic reviews on case-fatality ratios, and the effects 
of HIV and ART on tuberculosis incidence in children.
Methods
For every country, we used WHO estimates of tuberculosis 
incidence in children, WHO-compiled notification data 
from National Tuberculosis Programmes, and UNAIDS-
estimated paediatric HIV and ART prevalence, with 
recent findings of case-fatality ratios.17 Figure 1 shows the 
modelling process. Table 1 presents corresponding 
parameters, data sources, and distributional assumptions 
characterising input uncertainty.
We started with WHO-estimated tuberculosis incidence 
in children younger than 15 years for every country 
for 2015.5 Since the 2015 Global tuberculosis report,4 these 
have been based on an ensemble combination of methods 
proposed by Dodd and colleagues6 and Jenkins and 
colleagues.8 We used country point-estimates 
and uncertainty intervals to parameterise gamma 
distributions representing country paediatric tuberculosis 
incidence. We disaggregated these estimates for the 
younger than 15 years age group into younger than 
5 years and those aged 5–14 years using the country-level 
incidence fraction in each age group from Dodd and 
colleagues,7 modelled as a country-specific beta 
distribution.
The notification data represent tuberculosis cases 
reported to WHO by each country in the two age groups 
Research in context
Evidence before this study
We searched PubMed without language or date restrictions for 
all records matching “(TB or tuberc*) and (child* or paed* or 
ped*) and (mortality or death*) and (burden or estimate or 
epidem* or global)” in any field, returning 1231 records. 
We found no articles estimating the global mortality due to 
tuberculosis in children younger than 15 years. Patton and 
colleagues estimated 17 000 deaths due to tuberculosis in the 
10–14 age group for 2004. In 2012, WHO first produced 
estimates of tuberculosis mortality in children younger than 
15 years, estimating 64 000 HIV-negative children died from 
tuberculosis in 2011. In 2016, using vital registration data,  
WHO estimated that 210 000 children younger than 15 years 
(HIV-positive and HIV-negative) died from tuberculosis in 2015. 
No estimates exist for tuberculosis mortality in children 
younger than 5 years.
Added value of this study
We produced a global mortality burden estimate in children 
younger than 15 years using a complementary approach not 
dependent on vital registration data. We estimated that 
tuberculosis caused nearly a quarter of a million deaths in 
children younger than 15 years of age in 2015. More than 
80% of these deaths are in children younger than 5 years of age, 
which would make tuberculosis a top ten cause of death in this 
age group that is missing from all previous analyses. More than 
96% of deaths occurred in children not receiving 
anti-tuberculosis treatment.
Implications of all the available evidence
Tuberculosis is a key unrecognised component of child 
mortality. Mortality could be drastically reduced with increased 
treatment coverage.
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(<5 years and 5 to <15 years). In our main analysis, we 
assumed all notified child cases had received treatment, 
and that the difference between the estimated number of 
incident cases and those notified by the programme 
represented untreated cases.
To disaggregate tuberculosis incidence by HIV and 
ART status, we combined country-level UNAIDS 
paediatric HIV prevalence estimates (h) and ART 
coverage in children with HIV (α) (appendix shows 
missing data assumptions) with data from a recent 
child-specific systematic review on the incidence rate 
ratio for incident tuberculosis with respect to UNAIDS 
country HIV prevalence estimates (ρ), and the protective 
effect of ART against tuberculosis disease (hazard 
ratio τ; not country specific).18 Specifically, we assumed 
that the fraction of the tuberculosis incidence in each 
HIV and ART category was proportional to (1–h) for 
HIV-negative children, to ρ.h.(1–α) for HIV-positive 
children not on ART, and to ρ.h.α.τ for HIV-positive 
children on ART. We assumed that levels of treatment 
for tuberculosis did not vary by HIV or ART status.
For children who did not receive tuberculosis 
treatment, we took case-fatality ratios for HIV-negative 
children younger than 5 years and those aged 5–14 years 
from a recent systematic review and meta-analysis.17 We 
assumed case-fatality ratios in untreated HIV-negative 
children were the same as case-fatality ratios from the 
pre-chemotherapy era. Estimates were unavailable for 
case-fatality ratios in HIV-positive children with 
tuberculosis who did not receive tuberculosis treatment. 
For this group, we therefore elicited beta distribution 
parameters characterising the case-fatality ratios in 
children younger than 5 years and those aged 5–14 years 
(stratified by ART status) from six clinicians with relevant 
experience using the roulette method provided by 
MATCH (appendix).19
For children who did receive tuberculosis treatment, 
case-fatality ratio estimates from the same meta-analysis17 
were available for HIV-negative children younger than 
5 years and those aged 5–14 years. This review also 
presented US data stratified by HIV status from before 
and after the introduction of ART. We used a regression 
model for these data to produce a joint posterior for the 
odds ratios of death given HIV and ART status, 
accounting for time period (table 1 and appendix).
Uncertainty in parameters and inputs was included 
using 10 000 samples with a Latin hypercube design, and 
distributional assumptions (table 1). Results for 2015 
were aggregated by WHO region, and presented by 
treatment type, age group, and HIV status using median 
values as point estimates, and the 95 percentile ranges as 
uncertainty intervals. Median country estimates of per-
person mortality were mapped. For countries with 
UNAIDS estimates of paediatric HIV prevalence higher 
than 0·1%, we calculated the percentage of HIV infection 
among incident paediatric tuberculosis and among 
paediatric tuberculosis deaths.
All analyses were done with R.20 Our reporting follows 
the GATHER guidelines.21
Sensitivity analyses
To explore sensitivity to the assumption that the difference 
between estimated incidence and notified cases 
represents untreated cases, we considered the ten 
countries with highest estimated number of deaths from 
tuberculosis in our model and assumed a certain 
proportion of children were treated but not notified. 
These proportions were assumed to be the same as the 
fraction of all tuberculosis cases treated outside the 
National Tuberculosis Programme sector when data were 
available (appendix).
To explore the sensitivity of our results to elicited values 
for case-fatality ratio in untreated HIV-positive children, 
we also generated results using the conservative 
assumption that case-fatality ratios in untreated HIV-
positive children are the same as those in HIV-negative 
children (irrespective of ART status).
Data sharing
Scripts for data cleaning, as well as all subsequent merging 
and data handling are available on github. This repository 
Figure 1: Modelling data sources and stages
CFRs=Case-fatality ratios.
WHO country tuberculosis incidence estimates 
and uncertainty in children (aged <15 years)
Country tuberculosis incidence in children 
(aged <5 and 5 to <15 years)
Country
notifications
Dodd/Seddon model
Jenkins et al
CFRs
Elicited
CFRs
UNAIDS +
Dodd et al
Country tuberculosis incidence not 
treated in HIV– children (aged <5 
and 5 to <15 years)
Country tuberculosis incidence not 
treated in HIV+ or ART+ children 
(aged <5 and 5 to <15 years)
Country tuberculosis incidence not 
treated in HIV+ or ART– children 
(aged <5 and 5 to <15 years)
All tuberculosis deaths in country in 
untreated children (aged <5 and 
5 to <15 years)
Country tuberculosis incidence not 
treated in children (aged <5 and 
5 to <15 years)
Country tuberculosis incidence 
treated in HIV– children (aged <5 
and 5 to <15 years)
Country tuberculosis incidence 
treated in HIV+ or ART+ children 
(aged <5 and 5 to <15 years)
Country tuberculosis incidence 
treated in HIV+ or ART– children 
(aged <5 and 5 to <15 years)
All tuberculosis deaths in country in 
treated children (aged <5 and 
5 to <15 years)
Country tuberculosis incidence 
treated in children (aged <5 and 
5 to <15 years)
See Online for appendix
For all input and modelling 
data see https://github.com/
petedodd/4PM
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also includes all input data, model analysis scripts, and a 
set of test output graphs around representation of input 
parameter uncertainty. It also contains additional output 
data, including country-level estimates.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
Results
We estimated that 239 000 (95% UI 194 000–298 000) 
children younger than 15 years died from tuberculosis 
worldwide in 2015, with 191 000 (132 000–257 000) cases 
being in children younger than 5 years. This varied by 
region, with the WHO southeast Asia and Africa regions 
accounting for more than 70% of deaths (table 2). Per-
person tuberculosis mortality in children was highest in 
countries in sub-Saharan Africa with high annual 
tuberculosis incidences (figure 2), whereas absolute 
burden was highest in populous countries, with the top 
five burdens being in India, Nigeria, China, Indonesia, 
and Democratic Republic of the Congo (figure 3). 191 000 
(80%, 132 000–257 000) of tuberculosis deaths occurred 
in children younger than 5 years, and almost all 
(228 000 [96%]) occurred in children not on treatment 
(table 2, figure 4).
We estimated about 40 000 (17%) deaths from 
tuberculosis in HIV-positive children; most of these were 
in Africa, where 31 000 (36%, 19 000–59 000) child 
tuberculosis deaths were associated with HIV. For the 
50 countries with UNAIDS paediatric HIV prevalence 
higher than 0·1%, the median paediatric HIV prevalence 
was 0·2%, the median prevalence among incident 
paediatric tuberculosis cases was 13%, and the median 
prevalence among paediatric tuberculosis deaths 
was 27% (appendix). For South Africa, with one of the 
estimated highest HIV prevalence among paediatric 
tuberculosis deaths, the paediatric HIV prevalence was 
1·5% (240 000, 95% UI 210 000–260 000), and we 
estimated 35% HIV prevalence in incident tuberculosis 
(11 200, 1800–27 100) and 69% (2900, 95% UI 400–11 800) 
HIV prevalence in tuberculosis deaths.
Our sensitivity analysis in which case-fatality ratios 
were assumed to be the same in HIV-positive and HIV-
negative children not receiving tuberculosis treatment 
did not substantially change the global estimates. Global 
estimates reduced to 218 000 (95% UI 176 000–270 000) 
for children younger than 15 years and 179 000 
(124 000–240 000) for children younger than 5 years; an 
overall reduction of about 24 000, mostly in the WHO 
Africa region.
Changing the assumption that absence of case 
notification represents absence of treatment also did not 
have a large effect on the global estimates. The ten 
countries with highest paediatric tuberculosis mortality 
Source Value (95% CI) Distribution
Tuberculosis country incidence in children (aged <15 years) WHO5 Country-specific Gamma
Tuberculosis notifications in children (aged <5 years and 5–14 years) WHO5 Country-specific NA
Fraction of incidence in children <5 years for country Dodd and colleagues7 Country-specific Beta
HIV prevalence in children aged <15 years UNAIDS Country-specific Gamma
ART coverage in children aged <15 years UNAIDS Country-specific Gamma
Incidence rate ratio for tuberculosis if HIV-positive Dodd and colleagues18 77·8 (8·4–736·6)* LN (4·36, 1·14)
Hazard ratio for tuberculosis if HIV-positive on ART Dodd and colleagues18 0·3 (0·21–0·39) LN (–1·20, 0·15)
Case-fatality ratio children aged <5 years, treated for tuberculosis, HIV-negative Jenkins and colleagues17 1·9 (0·5–7·1) LN (–3·96, 0·65)
Case-fatality ratio children aged <5 years, untreated, HIV-negative Jenkins and colleagues17 43·6 (36·8–50·6) LN (–0·83, 0·08)
Case-fatality ratio children aged <5 years, untreated, HIV-positive, no ART Elicited 90·0 (77·8–96·9) Beta (33·18, 3·98)
Case-fatality ratio children aged <5 years, untreated, HIV-positive, on ART Elicited 63·5 (30·0–90·1) Beta (5·08, 3·98)
Case-fatality ratio children aged 5–14 years, treated for tuberculosis, HIV-
negative
Jenkins and colleagues17 0·8 (0·3–2·1) LN (–4·83, 0·48)
Case-fatality ratio children aged 5–14 years, untreated, HIV-negative Jenkins and colleagues17 14·9 (11·5–19·1) LN (–1·90, 0·13)
Case-fatality ratio children aged 5–14 years, untreated, HIV-positive, no ART Elicited 87·4 (67·4–97·2) Beta (16·18, 2·64)
Case-fatality ratio children aged 5–14 years, untreated, HIV-positive, on ART Elicited 45·7 (12·4–82·6) Beta (2·89, 3·33)
Odds ratio of death on tuberculosis treatment (HIV-positive or no ART vs no HIV) Jenkins and colleagues17 13·9 (5·4–36·2) logit-multivariate normal 
(appendix)
Odds ratio of death on tuberculosis treatment (HIV-positive or on ART vs no HIV) Jenkins and colleagues17 7·8 (2·3–27·0) logit-multivariate normal 
(appendix)
Data are n (95% CI) unless stated otherwise. LN=log-normal distribution. NA=not applicable. ART=antiretroviral therapy. *From a random-effects meta-analysis of data from 
Dodd and colleagues.18 When not otherwise stated, distribution parameters were established by matching median and variance.
Table 1: Data inputs, sources, and distributional characterisation of uncertainty
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accounted for 71% (170 000, 126 000–228 000) of global 
tuberculosis deaths in children. The assumption that a 
country-specific percentage of treated children who 
received tuberculosis treatment were not notified in the 
ten countries with the highest estimated paediatric 
tuberculosis mortality (appendix shows country-specific 
percentages used) reduced the number of deaths in 
children younger than 15 years to 218 000 (95% UI 
169 000–282 000) and deaths in children younger than 
5 years to 177 000 (120 000–244 000).
Discussion
Our case-fatality-based analysis suggests that 
239 000 children younger than 15 years died from 
tuberculosis in 2015, with 191 000 deaths occurring in 
children younger than 5 years (>80% of the deaths 
in children aged <15 years). Almost all of these 
deaths (>96%) occurred in children who were not 
receiving treatment for tuberculosis. Recent estimates 
of low mortality rates in children on treatment 
(<1% mortality)17 imply that the number of paediatric 
tuberculosis deaths could be roughly halved if the 
case-detection ratio for children were improved from its 
current value of approximately one in three to the two in 
three currently achieved in adults, or reduced by more 
than ten times if all children with tuberculosis were 
given treatment.
Most deaths were in the WHO Africa and southeast 
Asia regions, both for under-5 and under-15 mortality; 
the highest individual country mortality was found in 
India, Nigeria, China, Indonesia, and the Democratic 
Republic of the Congo. All these countries are on the 
current WHO list of 30 high tuberculosis burden 
countries; all are populous, with tuberculosis incidence 
rates under 400 per 100 000 per year. About 17% of deaths 
were in children with HIV. Per-person tuberculosis 
mortality was highest in sub-Saharan Africa, where 
roughly 36% of tuberculosis deaths were in children 
infected with HIV. The average case-fatality rate for 
tuberculosis in children globally was about 24%.
Our 191 000 estimated tuberculosis deaths in children 
younger than 5 years implies that tuberculosis should rank 
as a major cause of death in children younger than 5 years 
worldwide, despite not appearing in the 2016 CHERG 
Received tuberculosis 
treatment 
(HIV-negative)
Did not receive 
tuberculosis treatment 
(HIV-negative)
Received tuberculosis 
treatment (HIV-positive)
Did not receive 
tuberculosis treatment 
(HIV-positive)
Total mortality Mortality rate 
per 100 000
Age <5 years
AFR 651 (368– 1360) 44 700 (30 600– 62 100) 1900 (776 – 5500) 173 00 (9160–37 500) 66 100 (47 000–90 700) 41 (29– 56)
AMR 93 (61–152) 3910 (2180– 5900) 27 (6–152) 84 (21–422) 4180 (2380– 6210) 5 (3–8)
EMR 330 (163–837) 10 500 (3510– 21 000) 34 (7–180) 185 (41–826) 11 100 (4030– 21 800) 13 (5–27)
EUR 72 (47–134) 4460 (2610–6500) 1 (0–7) 17 (4–101) 4560 (2710– 6610) 8 (4–11)
SEA 1000 (506–2130) 71 400 (25 300– 127 000) 248 (53–1190) 2620 (303–20 200) 77 400 (27 700–137 000) 43 (15–76)
WPR 369 (140–1170) 25 300 (10 500– 41 500) 15 (2–110) 219 (53 – 905) 26 100 (11 300–42 300) 22 (9–35)
Total 2690 (1850– 4180) 161 000 (108 000–223 000) 2360 (1100– 6020) 22 000 (11 800–47 600) 191 000 (132 000–257 000) 28 (19–38)
Age 5 to <15 years
AFR 312 (216–480) 9970 (5910–15800) 937 (472–2090) 10 200 (4760–24 200) 21 900 (13 200–37 400) 8 (5–14)
AMR 52 (38–75) 968 (430–1670) 13 (3–67) 51 (10–319) 1120 (538–1880) 0 (0–1)
EMR 270 (150–566) 976 (336–3880) 25 (6–118) 62 (7–390) 1410 (649–4370) 1 (0–3)
EUR 61 (44–89) 786 (338–1500) 1 (0–6) 7 (1–60) 867 (406–1570) 0 (0–1)
SEA 1070 (612–2070) 11 300 (2110–30400) 302 (58–2080) 889 (29–9910) 14 400 (3700–38 000) 3 (1–10)
WPR 228 (128–438) 6280 (1970–12400) 18 (3–133) 107 (20–572) 6730 (2370–12 800) 3 (1–5)
Global 2050 (1510–3100) 31 500 (18600–51400) 1430 (738–3380) 12 200 (5920–28 800) 48 400 (30 900–75 800) 3 (2–6)
Age 0 to <15 years
AFR 978 (640– 1710) 54 900 (42 200– 70 400) 2890 (1320–7160) 28 200 (16 300–54 800) 88 600 (71 700–113 000) 21 (17–26)
AMR 148 (111– 207) 4890 (3610– 6460) 42 (10–209) 165 (58–543) 5310 (3990–6920) 2 (1–3)
EMR 625 (381– 1190) 11 600 (5380– 21 700) 62 (15–286) 277 (86–988) 12 700 (6370–22900) 5 (2–10)
EUR 136 (103– 200) 5250 (3870– 6960) 3 (0–13) 26 (8–143) 5440 (4050– 7140) 3 (2– 4)
SEA 2140 (1360–3580) 83 100 (48 200– 132 000) 574 (123–3140) 4050 (781–25 400) 92 500 (55 100–145 000) 17 (10–26)
WPR 616 (337–1410) 31 800 (21 000 – 44 800) 35 (7–230) 349 (98–1330) 32900 (22 100–46 000) 9 (6–13)
Total 4810 (3710–6590) 193 000 (151 000–247 000) 3900 (1960–8670) 35 000 (20 500–67 400) 239 000 (194 000–298 000) 12 (10–15)
Data are n (95% UI). AFR=African Region. AMR=Region of the Americas. EMR=Eastern Mediterranean Region. EUR=European Region. SEA=Southeast Asia Region. WPR=Western Pacific Region. Rounding and the 
use of medians mean that the 0 to <5 and 5 to <15 entries will not add up to those in the 0 to <15 section.
Table 2: Number of deaths due to tuberculosis in children in 2015, by age group, WHO region, and HIV and tuberculosis treatment status, and mortality rate by age group
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estimates, which were based on both vital registration and 
verbal autopsy data. Directly comparing our estimate 
for 2015 of 191 000 tuberculosis deaths in children younger 
than 5 years with the estimates for 2015 (for children aged 
1–59 months) reported by Liu and colleagues1 suggests that 
tuberculosis might be the sixth highest cause of death in 
the 1–59 month age group, causing more deaths than 
meningitis, AIDS, measles, and pertussis. Some deaths 
ascribed to pneumonia, meningitis, and AIDS may have 
been caused by tuberculosis. However, some tuberculosis 
deaths were probably not represented in these global 
mortality estimates, and thus that overall estimates are too 
low. The extent of reclassification, and implications for 
total child mortality are unclear. To achieve better estimates 
of the burden of tuberculosis mortality in children, new 
methods are needed that can leverage vital registration 
while accounting for its imperfections.
Our estimate for tuberculosis mortality in children 
younger than 15 years is similar to the WHO estimate 
of 210 000, which was based on an independent approach 
using vital registration data and imputation using child-to-
adult mortality rate ratios. A complementary approach 
based on case-fatality ratio offers a way to avoid some of 
the major limitations of methods based on vital registration 
and verbal autopsy. In view of the current diagnostic 
capacity and the state of vital registration systems in 
settings with high tuberculosis burdens, estimates based 
on vital registration and verbal autopsy data are highly 
sensitive to the assumptions made in adjusting primary 
data for misclassification and underdiagnosis. Additionally, 
any biases resulting from these assumptions will be 
perpetuated during extrapolations of these vital registration 
and verbal autopsy data to countries that do not collect 
such data. Moreover, the uncertainty associated with these 
assumptions is not well characterised because population-
based autopsy studies that establish the true causes of 
childhood mortality are rare. Thus, there has been 
substantial volatility in vital-registration-based estimates 
Figure 2: Mortality rate from tuberculosis for children (A) aged <5 years in 2015 (tuberculosis deaths in children per 100 000 children) and (B) <15 years 
in 2015 (tuberculosis deaths in children per 100 000 children)
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20–40
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80–120
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10–20
20–40
40–80
80–120
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B
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of childhood tuberculosis deaths; the increase from 
136 000 estimated deaths in 2014 to 210 000 deaths in 2015 
was largely attributable to new data availability from India, 
a change which then fed into extrapolations to many other 
countries, suggesting that the assumptions made for the 
2014 estimates were probably inaccurate. By contrast, the 
case-fatality ratio approach uses assumptions based on 
decades of scientific literature whose uncertainty can be 
quantified. Therefore, we believe that such an approach is 
important for contributing to the development of more 
rigorous estimates, even as efforts are made to strengthen 
systems for diagnosis and mortality surveillance.
As with any method, the case-fatality ratio approach 
has limitations. First, given the excellent treatment 
outcomes in children (<1% mortality in children 
<15 years) and the high case-fatality ratios in children 
who do not receive treatment (22% mortality in children 
<15 years),17 our estimate is sensitive to the assumption 
that children who are not notified as having tuberculosis 
do not receive tuberculosis treatment. However, our 
sensitivity analysis assuming high rates of non-notified 
treatment in the highest burden reduced our estimates 
of total childhood and under-5 tuberculosis mortality 
by less than 10%, still making tuberculosis the sixth 
largest contributor to under-5 mortality worldwide. We 
also neglected the potential for overdiagnosis on clinical 
grounds to substantially impact on our estimates.
Our estimates are also limited by not having case-fatality 
ratios for every potentially meaningful subgroup of 
children with tuberculosis. Because case-fatality ratios for 
children with tuberculosis who do not receive tuberculosis 
treatment were not available from recent studies, we 
assumed that these children had the same risk of death as 
children in the era before effective treatment was available 
in populations in Europe and the USA. However, in view 
of potential differences in underlying child health, these 
case-fatality ratios may be different today and in other 
settings. The case-fatality ratios we used were based on 
death within 1 year of diagnosis; we modelled progression 
to disease and death as occurring within 1 year of infection, 
which neglects the influence of trends in annual risks of 
infection via children who take longer to progress and die. 
For comparison, the case-fatality ratio for untreated HIV-
negative adult tuberculosis cases (over their longer disease 
course) is thought to be 70% in smear-positive and 20% in 
smear-positive, culture-positive cases.22 Finally, we have not 
considered any potential protection against mortality 
conferred by Bacillus Calmette-Guérin (BCG) vaccination 
in tuberculosis disease, independent of protection against 
incidence. The review by Jenkins and colleages17 was 
unable to estimate case-fatality ratios among BCG-
vaccinated children and a recent review and meta-analysis23 
was suggestive of only a weak or absent additional effect of 
BCG against mortality independent of disease.
We assumed a uniform prevalence of HIV and ART 
coverage by age among children, and that the likelihood of 
tuberculosis diagnosis and notification is not affected by 
Figure 4: Mosaic plot with areas showing the proportion of tuberculosis deaths in children aged <15 years 
in 2015, by age group, tuberculosis treatment status, and HIV infection status
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Figure 3: Number of deaths from tuberculosis in children aged <15 years 
in 2015, for the 20 countries with highest paediatric tuberculosis mortality
Error bars denote IQR.
Articles
e905 www.thelancet.com/lancetgh   Vol 5   September 2017
HIV status. We used an incident rate ratio for incident 
tuberculosis given HIV derived from comparing 
systematic review data on HIV prevalence in child 
tuberculosis cases with UNAIDS paediatric HIV 
prevalence. This might be subject to various biases, and is 
uncertain due to high between-country variability. 
However, it is specific to our input data, and yields HIV 
prevalence in child tuberculosis cases and deaths that 
accords with observations. Moreover, our estimates are 
within 10% of the vital-registration-based WHO estimates 
of paediatric HIV/tuberculosis mortality for the African 
and southeast Asia regions, which include most HIV and 
tuberculosis deaths. Data were also unavailable to inform 
case-fatality ratios for HIV-positive children who are not 
treated for tuberculosis, and these were based on expert 
opinion. However, our sensitivity analysis assuming HIV-
negative case-fatality ratios applied to HIV-positive children 
resulted in a reduction in our total estimate of about 10%.
A major strength of our work is its independence from 
vital registration data, which is absent or of poor quality 
in many countries with a high tuberculosis burden and 
likely to miss a large and poorly quantified fraction of 
tuberculosis deaths. Instead, it makes use of recent 
evidence from updated childhood tuberculosis estimates, 
current data about HIV prevalence and ART coverage, 
and a systematic review and meta-analysis of case-fatality 
ratios. Another strength is our thorough treatment of 
uncertainty and investigation of the effect of key 
assumptions.
Reducing childhood deaths from tuberculosis requires 
more children to be reached, diagnosed, and treated. 
Developing an acceptable diagnostic test that reliably 
identified tuberculosis disease in children would be 
hugely beneficial, but an increasing willingness to treat 
children clinically for tuberculosis disease, without 
requiring confirmation of diagnosis, would also reduce 
mortality. However, it would probably mean an increase 
in the number of children treated unnecessarily for 
tuberculosis and we as a society would need to consider 
whether this is an approach we are prepared to follow.
  Many other methods to reduce child deaths due to 
tuberculosis already exist, but to realise their protective 
benefit, health systems must invest in ensuring that they 
are fully implemented. For instance, household contact 
investigations can ensure that children with tuberculosis 
receive prompt treatment and that other exposed children 
can be given preventive treatment to reduce the risk of 
subsequent tuberculosis.24,25 However, logistical and 
structural barriers have hampered the implementation of 
routine contact investigations,26 and only 7% of young 
child contacts received preventive treatment in 2015.5 
Additionally, because children with HIV are at an increased 
risk of both developing tuberculosis and dying from it, 
prevention of mother-to-child transmission of HIV and 
ART initiation for children who are HIV-positive should 
reduce child tuberculosis deaths. However, in 2015, nearly 
a quarter of pregnant women living with HIV did not have 
access to services to prevent mother-to-child transmission, 
and half of all children living with HIV were not receiving 
ART.27 Finally, addressing other risk factors for tuberculosis, 
such as undernutrition, crowding, and poverty can all play 
a role in reducing tuberculosis deaths in children.
Tuberculosis is one of the top ten causes of death in 
children and a key missing component in previous 
analyses of under-5 mortality. Almost all these deaths 
occur in children who are not being treated for 
tuberculosis, implying that efforts to identify children at 
risk of tuberculosis, diagnose children with tuberculosis, 
and treat them appropriately must be implemented to 
substantially reduce tuberculosis mortality in children.
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